Transverse myelitis

Autoimmunity Reviews

Volumn 11, Issue 3, 2012, Pages 231-248

  Borchers, Andrea T ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti phospholipid antibodies; Autoimmunity; Immunization; Infection; Transverse myelitis

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; COPPER; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACUTE TRANSVERSE MYELITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BRAIN RADIOGRAPHY; CEREBROSPINAL FLUID ANALYSIS; COPPER DEFICIENCY; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ETHNICITY; GENDER; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC DISEASE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INCIDENCE; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; MYELITIS; MYELOGRAPHY; MYELOOPTIC NEUROPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; PLASMAPHERESIS; PREDICTOR VARIABLE; PROGNOSIS; RECURRENT DISEASE; RELAPSE; REVIEW; SARCOIDOSIS; SEROLOGY; SEROPREVALENCE; SJOEGREN SYNDROME; SUBACUTE COMBINED DEGENERATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; AUTOANTIGENS; CHILD; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MYELITIS, TRANSVERSE; SPINAL CORD;

EID: 84855940328     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.05.018     Document Type: Review

References (166)

1. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002, 59:499-505. Transverse Myelitis Consortium Working Group.
2. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
3. Miller D.H., Weinshenker B.G., Filippi M., Banwell B.L., Cohen J.A., Freedman M.S., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008, 14:1157-1174.
4. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
5. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
6. Kalluri S.R., Illes Z., Srivastava R., Cree B., Menge T., Bennett J.L., et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010, 67:1201-1208.
7. Jarius S., Probst C., Borowski K., Franciotta D., Wildemann B., Stoecker W., et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010, 291:52-56.
8. Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008, 65:913-919.
9. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235-1243.
10. Mader S., Lutterotti A., Di Pauli F., Kuenz B., Schanda K., Aboul-Enein F., et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 2010, 5:e10455.
11. Collongues N., Marignier R., Zéphir H., Papeix C., Blanc F., Ritleng C., et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010, 74:736-742.
12. Cabrera-Gómez J.A., Bonnan M., González-Quevedo A., Saiz-Hinarejos A., Marignier R., Olindo S., et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler 2009, 15:828-833.
13. Tan K., Shuguna M., Goh K.Y., Lim S.A., Umapathi T. The seroprevalence of NMO-IgG in Singapore: a pilot study. Neurol Asia 2008, 13:205-206.
14. Pandit L. Neuromyelitis optica antibody (NMO-IgG) status in Indian patients with multiple sclerosis and allied demyelinating disorders. Neurol Asia. 2008, 13:175-178.
15. Saiz A., Zuliani L., Blanco Y., Tavolato B., Giometto B., Graus F. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007, 254:1233-1237.
16. Marignier R., De Sèze J., Vukusic S., Durand-Dubief F., Zéphir H., Vermersch P., et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 2008, 14:440-445.
17. Nakashima I., Fujihara K., Miyazawa I., Misu T., Narikawa K., Nakamura M., et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006, 77:1073-1075.
18. Kim K.K. NMO-IgG and opticospinal multiple sclerosis and idiopathic recurrent myelitis. Mult Scler 2006, 12:S157.
19. Tanaka K., Tani T., Tanaka M., Saida T., Idezuka J., Yamazaki M., et al. Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler 2007, 13:850-855.
20. Matsuoka T., Matsushita T., Kawano Y., Osoegawa M., Ochi H., Ishizu T., et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007, 130:1206-1223.
21. Matsushita T., Isobe N., Matsuoka T., Shi N., Kawano Y., Wu X.M., et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009, 15:834-847.
22. Wu J.S., Matsushita T., Carroll W.M., Kira J., Mastaglia F.L., Kermode A.G. Low sensitivity of anti-aquaporin-4 antibody in multiple sclerosis, longitudinally extensive spinal cord lesions and neuromyelitis optica in Australians. Neurol Asia. 2007, 12:149-150.
23. Pittock S.J., Lennon V.A., de Seze J., Vermersch P., Homburger H.A., Wingerchuk D.M., et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008, 65:78-83.
24. Jarius S., Franciotta D., Bergamaschi R., Wright H., Littleton E., Palace J., et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
25. Kim S.H., Kim S.M., Vincent A., Ahn S.W., Hong Y.H., Park K.S., et al. Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. J Neurol 2010, 257:920-925.
26. Weinshenker B.G., Wingerchuk D.M., Vukusic S., Linbo L., Pittock S.J., Lucchinetti C.F., et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
27. Chan K.H., Ramsden D.B., Yu Y.L., Kwok K.H., Chu A.C., Ho P.W., et al. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. Eur J Neurol 2009, 16:310-316.
28. Adoni T., Lino A.M., da Gama P.D., Apostolos-Pereira S.L., Marchiori P.E., Kok F., et al. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler 2010, 16:81-86.
29. Matiello M., Lennon V.A., Jacob A., Pittock S.J., Lucchinetti C.F., Wingerchuk D.M., et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008, 70:2197-2200.
30. Wandinger K.P., Stangel M., Witte T., Venables P., Charles P., Jarius S., et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 2010, 62:1198-1200.
31. Kahlenberg J.M. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren's syndrome. Semin Arthritis Rheum 2010.
32. Javed A., Balabanov R., Arnason B.G., Kelly T.J., Sweiss N.J., Pytel P., et al. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 2008, 14:809-814.
33. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
34. Berman M., Feldman S., Alter M., Zilber N., Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981, 31:966-971.
35. Jeffery D.R., Mandler R.N., Davis L.E. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993, 50:532-535.
36. Klein N.P., Ray P., Carpenter D., Hansen J., Lewis E., Fireman B., et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010, 28:1062-1068.
37. Young J., Quinn S., Hurrell M., Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 2009, 15:1295-1302.
38. Torisu H., Kira R., Ishizaki Y., Sanefuji M., Yamaguchi Y., Yasumoto S., et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010, 32:454-462.
39. Banwell B., Kennedy J., Sadovnick D., Arnold D.L., Magalhaes S., Wambera K., et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009, 72:232-239.
40. Kaplin A.I., Krishnan C., Deshpande D.M., Pardo C.A., Kerr D.A. Diagnosis and management of acute myelopathies. Neurologist 2005, 11:2-18.
41. D'Cruz D.P., Mellor-Pita S., Joven B., Sanna G., Allanson J., Taylor J., et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004, 31:280-285.
42. Espinosa G., Mendizabal A., Minguez S., Ramo-Tello C., Capellades J., Olive A., et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2010, 39:246-256.
43. Rabadi M.H., Kundi S., Brett D., Padmanabhan R. Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010, 81:213-214.
44. Theodoridou A., Settas L. Demyelination in rheumatic diseases. Postgrad Med J 2008, 84:127-132.
45. Kovacs B., Lafferty T.L., Brent L.H., DeHoratius R.J. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000, 59:120-124.
46. Andrianakos A.A., Duffy J., Suzuki M., Sharp J.T. Transverse myelopathy in systemic lupus erythematosus. Report of three cases and review of the literature. Ann Intern Med 1975, 83:616-624.
47. Vincent T.L., Richardson M.P., Mackworth-Young C.G., Hawke S.H., Venables P.J. Sjögren's syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med 2003, 114:145-148.
48. de Seze J., Lanctin C., Lebrun C., Malikova I., Papeix C., Wiertlewski S., et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005, 65:1950-1953.
49. Cabrera-Gómez J.A., Kurtzke J.F., Gonzalez-Quevedo A., Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009, 256:35-44.
50. Cabre P., Heinzlef O., Merle H., Buisson G.G., Bera O., Bellance R., et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001, 56:507-514.
51. Kuroiwa Y., Igata A., Itahara K., Koshijima S., Tsubaki T. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1084 cases. Neurology 1975, 25:845-851.
52. Altrocchi P.H. Acute transverse myelopathy. Arch Neurol 1963, 9:111-119.
53. Lipton H.L., Teasdall R.D. Acute transverse myelopathy in adults. A follow-up study. Arch Neurol 1973, 28:252-257.
54. Ropper A.H., Miett T., Chiappa K.H. Absence of evoked potential abnormalities in acute transverse myelopathy. Neurology 1982, 32:80-82.
55. Christensen P.B., Wermuth L., Hinge H.H., Bømers K. Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol Scand 1990, 81:431-435.
56. de Seze J., Stojkovic T., Breteau G., Lucas C., Michon-Pasturel U., Gauvrit J.Y., et al. Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. Brain 2001, 124:1509-1521.
57. Bruna J., Martínez-Yélamos S., Martínez-Yélamos A., Rubio F., Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006, 12:169-173.
58. Kahloon A.A., Arif H., Baig S.M., Khawaja M.R. Characteristics of acute transverse myelitis at Aga Khan University Hospital, Karachi. J Pak Med Assoc 2007, 57:215-218.
59. Perumal J., Zabad R., Caon C., MacKenzie M., Tselis A., Bao F., et al. Acute transverse myelitis with normal brain MRI: long-term risk of MS. J Neurol 2008, 255:89-93.
60. Alvarenga M.P., Thuler L.C., Neto S.P., Vasconcelos C.C., Camargo S.G., Alvarenga M.P., et al. The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol 2010, 257:992-998. other publications by the first author are under Papais-Alvarenga.
61. Defresne P., Hollenberg H., Husson B., Tabarki B., Landrieu P., Huault G., et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003, 18:401-406.
62. Pidcock F.S., Krishnan C., Crawford T.O., Salorio C.F., Trovato M., Kerr D.A. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007, 68:1474-1480.
63. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003, 60:848-853.
64. Papais-Alvarenga R.M., Carellos S.C., Alvarenga M.P., Holander C., Bichara R.P., Thuler L.C. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008, 126:12-16.
65. Bichuetti D.B., Oliveira E.M., Souza N.A., Rivero R.L., Gabbai A.A. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler 2009, 15:613-619.
66. Bizzoco E., Lolli F., Repice A.M., Hakiki B., Falcini M., Barilaro A., et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009, 256:1891-1898.
67. Wu J.S., Zhang M.N., Carroll W.M., Kermode A.G. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry 2008, 79:1022-1026.
68. Rivera J.F., Kurtzke J.F., Booth V.J., Corona V.T.T. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 2008, 255:710-715.
69. O'Riordan J.I., Gallagher H.L., Thompson A.J., Howard R.S., Kingsley D.P., Thompson E.J., et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996, 60:382-387.
70. de Seze J., Lebrun C., Stojkovic T., Ferriby D., Chatel M., Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003, 9:521-525.
71. Kincaid O., Lipton H.L. Viral myelitis: an update. Curr Neurol Neurosci Rep 2006, 6:469-474.
72. Jaiser S.R., Winston G.P. Copper deficiency myelopathy. J Neurol 2010, 257:869-881.
73. Kumar N., Ahlskog J.E., Klein C.J., Port J.D. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology 2006, 48:78-83.
74. Vasconcelos O.M., Poehm E.H., McCarter R.J., Campbell W.W., Quezado Z.M. Potential outcome factors in subacute combined degeneration: review of observational studies. J Gen Intern Med 2006, 21:1063-1068.
75. Ropper A.H., Poskanzer D.C. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. Ann Neurol 1978, 4:51-59.
76. Yiu E.M., Kornberg A.J., Ryan M.M., Coleman L.T., Mackay M.T. Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: spectrum or separate entities?. J Child Neurol 2009, 24:287-296.
77. Kalra V., Sharma S., Sahu J., Sankhyan N., Chaudhry R., Dhawan B., et al. Childhood acute transverse myelitis: clinical profile, outcome, and association with antiganglioside antibodies. J Child Neurol 2009, 24:466-471.
78. Dunne K., Hopkins I.J., Shield L.K. Acute transverse myelopathy in childhood. Dev Med Child Neurol 1986, 28:198-204.
79. Paine R.S., Byers R.K. Transverse myelopathy in childhood. AMA Am J Dis Child 1953, 85:151-163.
80. Agmon-Levin N., Kivity S., Szyper-Kravitz M., Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 2009, 18:1198-1204.
81. al Deeb S.M., Yaqub B.A., Bruyn G.W., Biary N.M. Acute transverse myelitis. A localized form of postinfectious encephalomyelitis. Brain 1997, 120(Pt 7):1115-1122.
82. Misra U.K., Kalita J., Kumar S. A clinical, MRI and neurophysiological study of acute transverse myelitis. J Neurol Sci 1996, 138:150-156.
83. Krishnan C., Kaplin A.I., Pardo C.A., Kerr D.A., Keswani S.C. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep 2006, 6:236-243.
84. Kalita J., Shah S., Kapoor R., Misra U.K. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry 2002, 73:154-159.
85. Bakshi R., Kinkel P.R., Mechtler L.L., Bates V.E., Lindsay B.D., Esposito S.E., et al. Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis. Eur J Neurol 1998, 5:35-48.
86. Chan K.H., Tsang K.L., Fong G.C., Ho S.L., Cheung R.T., Mak W. Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. Eur J Neurol 2006, 13:862-868.
87. Alper G., Petropoulou K.A., Fitz C.R., Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler 2010.
88. Banwell B., Tenembaum S., Lennon V.A., Ursell E., Kennedy J., Bar-Or A., et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008, 70:344-352.
89. Irani D.N., Kerr D.A. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet 2000, 355:901.
90. de Seze J., Peoc'h K., Ferriby D., Stojkovic T., Laplanche J.L., Vermersch P. 14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J Neurol 2002, 249:626-627.
91. Scott T.F. Nosology of idiopathic transverse myelitis syndromes. Acta Neurol Scand 2007, 115:371-376.
92. Sellner J., Luthi N., Buhler R., Gebhardt A., Findling O., Greeve I., et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol 2008, 15:398-405.
93. Cordonnier C., de Seze J., Breteau G., Ferriby D., Michelin E., Stojkovic T., et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol 2003, 250:1447-1452.
94. Pandit L., Rao S. Recurrent myelitis. J Neurol Neurosurg Psychiatry 1996, 60:336-338.
95. Scott T.F., Bhagavatula K., Snyder P.J., Chieffe C. Transverse myelitis. Comparison with spinal cord presentations of multiple sclerosis. Neurology 1998, 50:429-433.
96. García-Merino A., Blasco M.R. Recurrent transverse myelitis with unusual long-standing Gd-DTPA enhancement. J Neurol 2000, 247:550-551.
97. Seifert T., Enzinger C., Ropele S., Storch M.K., Strasser-Fuchs S., Fazekas F. Relapsing acute transverse myelitis: a specific entity. Eur J Neurol 2005, 12:681-684.
98. Kim K.K. Idiopathic recurrent transverse myelitis. Arch Neurol 2003, 60:1290-1294.
99. Chan K.H., Tsang K.L., Fong G.C., Cheung R.T., Ho S.L. Idiopathic severe recurrent transverse myelitis: a restricted variant of neuromyelitis optica. Clin Neurol Neurosurg 2005, 107:132-135.
100. Masuhr F., Busch M., Wetzel K., Harms L., Schielke E. Relapsing myelitis with pathological visual evoked potentials: a case of neuromyelitis optica?. Eur J Neurol 2002, 9:430-432.
101. Hummers L.K., Krishnan C., Casciola-Rosen L., Rosen A., Morris S., Mahoney J.A., et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology 2004, 62:147-149.
102. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
103. Ghezzi A., Bergamaschi R., Martinelli V., Trojano M., Tola M.R., Merelli E., et al. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol 2004, 251:47-52.
104. Papais-Alvarenga R.M., Miranda-Santos C.M., Puccioni-Sohler M., de Almeida A.M., Oliveira S., Basilio De Oliveira C.A., et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 2002, 73:429-435.
105. Sellner J., Hemmer B., Muhlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 2010, 34:371-379.
106. Wingerchuk D.M., Pittock S.J., Lucchinetti C.F., Lennon V.A., Weinshenker B.G. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603-605.
107. Sahraian M.A., Moinfar Z., Khorramnia S., Ebrahim M.M. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 2010, 17:794-799.
108. Pittock S.J., Lennon V.A., Krecke K., Wingerchuk D.M., Lucchinetti C.F., Weinshenker B.G. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390-396.
109. Merle H., Olindo S., Bonnan M., Donnio A., Richer R., Smadja D., et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007, 114:810-815.
110. Jeffery A.R., Buncic J.R. Pediatric Devic's neuromyelitis optica. J Pediatr Ophthalmol Strabismus 1996, 33:223-229.
111. Lotze T.E., Northrop J.L., Hutton G.J., Ross B., Schiffman J.S., Hunter J.V. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008, 122:e1039-e1047.
112. McKeon A., Lennon V.A., Lotze T., Tenenbaum S., Ness J.M., Rensel M., et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008, 71:93-100.
113. de Seze J., Stojkovic T., Ferriby D., Gauvrit J.Y., Montagne C., Mounier-Vehier F., et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002, 197:57-61.
114. Matiello M., Kim H.J., Kim W., Brum D.G., Barreira A.A., Kingsbury D.J., et al. Familial neuromyelitis optica. Neurology 2010, 75:310-315.
115. Akkad W., Salem B., Freeman J.W., Huntington M.K. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch Neurol 2010, 67:1018-1020.
116. Bogdanos D.P., Smith H., Ma Y., Baum H., Mieli-Vergani G., Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol 2005, 12:217-224.
117. Santos-García D., Arias-Rivas S., Dapena D., Arias M. Infección remota por virus de la hepatitis B y enfermedad desmielinizante multifásica: ¿casualidad o causalidad?. Neurologia 2007, 22:542-546.
118. Matsui M., Kakigi R., Watanabe S., Kuroda Y. Recurrent demyelinating transverse myelitis in a high titer HBs-antigen carrier. J Neurol Sci 1996, 139:235-237.
119. Yuki N., Odaka M. Ganglioside mimicry as a cause of Guillain-Barré syndrome. Curr Opin Neurol 2005, 18:557-561.
120. Aberle J., Kluwe J., Pawlas F., Stellbrink H.J., Greten H. Severe myelitis following infection with Campylobacter enteritis. Eur J Clin Microbiol Infect Dis 2004, 23:134-135.
121. Baar I., Jacobs B.C., Govers N., Jorens P.G., Parizel P.M., Cras P. Campylobacter jejuni-induced acute transverse myelitis. Spinal Cord 2007, 45:690-694.
122. Drulovic J., Dujmovic I., Stojsavlevic N., Tripkovic I., Apostolski S., Levic Z., et al. Transverse myelopathy in the antiphospholipid antibody syndrome: pinworm infestation as a trigger?. J Neurol Neurosurg Psychiatry 2000, 68:249.
123. Krishnan C., Kaplin A.I., Graber J.S., Darman J.S., Kerr D.A. Recurrent transverse myelitis following neurobrucellosis: immunologic features and beneficial response to immunosuppression. J Neurovirol 2005, 11:225-231.
124. Watanabe K., Kim S., Nishiguchi M., Suzuki H., Watarai M. Brucella melitensis infection associated with Guillain-Barré syndrome through molecular mimicry of host structures. FEMS Immunol Med Microbiol 2005, 45:121-127.
125. Ang C.W., Tio-Gillen A.P., Groen J., Herbrink P., Jacobs B.C., Van Koningsveld R., et al. Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome. J Neuroimmunol 2002, 130:179-183.
126. Nishimura M., Saida T., Kuroki S., Kawabata T., Obayashi H., Saida K., et al. Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 1996, 140:91-95.
127. Tsiodras S., Kelesidis T., Kelesidis I., Voumbourakis K., Giamarellou H. Mycoplasma pneumoniae-associated myelitis: a comprehensive review. Eur J Neurol 2006, 13:112-124.
128. Kaplin A.I., Deshpande D.M., Scott E., Krishnan C., Carmen J.S., Shats I., et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005, 115:2731-2741.
129. Içöz S., Tüzün E., Kürtüncü M., Durmuş H., Mutlu M., Eraksoy M., et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010, 120:71-75.
130. Yanagawa K., Kawachi I., Toyoshima Y., Yokoseki A., Arakawa M., Hasegawa A., et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009, 73:1628-1637.
131. Correale J., Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004, 63:2363-2370.
132. Graber J.J., Allie S.R., Mullen K.M., Jones M.V., Wang T., Krishnan C., et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008, 196:124-132.
133. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
134. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
135. Jacob A., Weinshenker B.G., Violich I., McLinskey N., Krupp L., Fox R.J., et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
136. Weinstock-Guttman B., Miller C., Yeh E., Stosic M., Umhauer M., Batra N., et al. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler 2008, 14:1061-1067.
137. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
138. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224-1234.
139. Mobasheri A., Marples D., Young I.S., Floyd R.V., Moskaluk C.A., Frigeri A. Distribution of the AQP4 water channel in normal human tissues: protein and tissue microarrays reveal expression in several new anatomical locations, including the prostate gland and seminal vesicles. Channels (Austin) 2007, 1:29-38.
140. Nicchia G.P., Mastrototaro M., Rossi A., Pisani F., Tortorella C., Ruggieri M., et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57:1363-1373.
141. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
142. Pittock S.J., Weinshenker B.G., Lucchinetti C.F., Wingerchuk D.M., Corboy J.R., Lennon V.A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964-968.
143. Takano R., Misu T., Takahashi T., Sato S., Fujihara K., Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010, 75:208-216.
144. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131:3072-3080.
145. Nishiyama S., Ito T., Misu T., Takahashi T., Kikuchi A., Suzuki N., et al. A case of NMO seropositive for aquaporin-4 antibody more than 10years before onset. Neurology 2009, 72:1960-1961.
146. Jarius S., Paul F., Martins da Silva A., Leite M.I., Waters P., Littleton E., et al. Neuromyelitis optica and longitudinally extensive transverse myelitis following thymectomy for myasthenia gravis. Mult Scler 2007, 13:S159.
147. Hinson S.R., Pittock S.J., Lucchinetti C.F., Roemer S.F., Fryer J.P., Kryzer T.J., et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231.
148. Kinoshita M., Nakatsuji Y., Moriya M., Okuno T., Kumanogoh A., Nakano M., et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009, 20:508-512.
149. Sabater L., Giralt A., Boronat A., Hankiewicz K., Blanco Y., Llufriu S., et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 2009, 215:31-35.
150. Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., Dupree C., et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009, 66:617-629.
151. Vincent T., Saikali P., Cayrol R., Roth A.D., Bar-Or A., Prat A., et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008, 181:5730-5737.
152. Marignier R., Nicolle A., Watrin C., Touret M., Cavagna S., Varrin-Doyer M., et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010.
153. Jarius S., Franciotta D., Paul F., Ruprecht K., Bergamaschi R., Rommer P.S., et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010, 7:52.
154. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009, 66:630-643.
155. Jarius S., Franciotta D., Bergamaschi R., Wildemann B., Wandinger K.P. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 2010, 48:659-663.
156. Haase C.G., Schmidt S. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica. Neurosci Lett 2001, 307:131-133.
157. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009, 386:623-627.
158. Sharma R., Fischer M.T., Bauer J., Felts P.A., Smith K.J., Misu T., et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010, 120:223-236.
159. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
160. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010, 394:205-210.
161. Heerlein K., Jarius S., Jacobi C., Rohde S., Storch-Hagenlocher B., Wildemann B. Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci 2009, 276:184-186.
162. Cikes N., Bosnic D., Sentic M. Non-MS autoimmune demyelination. Clin Neurol Neurosurg 2008, 110:905-912.
163. Kim S.M., Waters P., Vincent A., Kim S.Y., Kim H.J., Hong Y.H., et al. Sjögren's syndrome myelopathy: spinal cord involvement in Sjögren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009, 15:1062-1068.
164. Birnbaum J., Petri M., Thompson R., Izbudak I., Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009, 60:3378-3387.
165. Delalande S., de Seze J., Fauchais A.L., Hachulla E., Stojkovic T., Ferriby D., et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004, 83:280-291.
166. Akman-Demir G., Mutlu M., Icoz S., Kurtuncu M., Yesilot N., Eraksoy M. Probable NMO IgG in Turkish patients with Devic's disease, and multiple sclerosis. Mult Scler 2006, 12:S157.